AtriCure’s (ATRC) “Buy” Rating Reiterated at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of AtriCure (NASDAQ:ATRC – Free Report) in a research report report published on Thursday,Benzinga reports. The brokerage currently has a $51.00 price objective on the medical device company’s stock. ATRC has been the subject of a number of other reports. Oppenheimer raised their price target […]
Needham & Company LLC reaffirmed their buy rating on shares of AtriCure (NASDAQ:ATRC – Free Report) in a research report report published on Thursday,Benzinga reports. The brokerage currently has a $51.00 price objective on the medical device company’s stock. ATRC has been the subject of a number of other reports. Oppenheimer raised their price target […]
